Earnings Outlook For Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
Biomarin Pharmaceutical (NASDAQ:BMRN) is set to release its latest quarterly earnings report on July 31, 2023. Analysts estimate an earnings per share (EPS) of $0.47. The company's past performance shows a pattern of beating EPS estimates but experiencing a drop in share price the following day. The stock is currently trading at $86.56 and has seen a 1.72% increase over the last 52-week period.
July 28, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biomarin Pharmaceutical is expected to report an EPS of $0.47 in its upcoming earnings. The company's history of beating EPS estimates but experiencing share price drops could impact investor sentiment.
The company's earnings report is a significant event that could influence its stock price. However, the pattern of share price drops following EPS beats adds uncertainty to the potential impact. The stock's positive performance over the past year may also influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100